Literature DB >> 25677399

Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome.

J R Ferraris1,2, V Ferraris1, A B Acquier3,4, P B Sorroche5, M S Saez5, A Ginaca6, C F Mendez3,4.   

Abstract

Haemolytic uraemic syndrome (HUS) is characterized by haemolytic anaemia, thrombocytopenia and acute renal failure. We studied the activation state of classical and alternative pathways of complement during the acute phase of Shiga toxin-associated HUS by performing a prospective study of 18 patients and 17 age-matched healthy controls to evaluate C3, C3c, C4, C4d, Bb and SC5b-9 levels. SC5b-9 levels were increased significantly in all patients at admission compared to healthy and end-stage renal disease controls, but were significantly higher in patients presenting with oliguria compared to those with preserved diuresis. C3 and C4 levels were elevated significantly at admission in the non-oliguric group when compared to controls. No significant differences were found for C4d values, whereas factor Bb was elevated in all patients and significantly higher in oliguric patients when compared to both controls and non-oliguric individuals. A positive and significant association was detected when Bb formation was plotted as a function of plasma SC5b-9 at admission. Bb levels declined rapidly during the first week, with values not significantly different from controls by days 3 and 5 for non-oligurics and oligurics, respectively. Our data demonstrate the activation of the alternative pathway of complement during the acute phase of Stx-associated HUS. This finding suggests that complement activation may represent an important trigger for the cell damage that occurs during the syndrome.
© 2015 British Society for Immunology.

Entities:  

Keywords:  HUS; acute renal injury; alternative pathway; complement

Mesh:

Substances:

Year:  2015        PMID: 25677399      PMCID: PMC4469161          DOI: 10.1111/cei.12601

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

Review 1.  Complement activation following oxidative stress.

Authors:  C D Collard; R Lekowski; J E Jordan; A Agah; G L Stahl
Journal:  Mol Immunol       Date:  1999 Sep-Oct       Impact factor: 4.407

2.  Letter: Serum-complement levels in haemolytic-uraemic syndrome.

Authors:  B S Kaplan; P D Thomson; G M MacNab
Journal:  Lancet       Date:  1973-12-29       Impact factor: 79.321

3.  Letter: Plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura.

Authors:  J S Cameron; R Vick
Journal:  Lancet       Date:  1973-10-27       Impact factor: 79.321

4.  The hemolytic-uremic syndrome. Renal status of 76 patients at long-term follow-up.

Authors:  C A Gianantonio; M Vitacco; F Mendilaharzu; G Gallo
Journal:  J Pediatr       Date:  1968-06       Impact factor: 4.406

5.  Complement activation after oxidative stress: role of the lectin complement pathway.

Authors:  C D Collard; A Väkevä; M A Morrissey; A Agah; S A Rollins; W R Reenstra; J A Buras; S Meri; G L Stahl
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

6.  Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1.

Authors:  C D Collard; M C Montalto; W R Reenstra; J A Buras; G L Stahl
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

7.  [Historical stages of Hemolytic Uremic Syndrome in Argentina (1964-2009)].

Authors:  Marcela Belardo
Journal:  Arch Argent Pediatr       Date:  2012-10       Impact factor: 0.635

Review 8.  Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.

Authors:  Amit X Garg; Rita S Suri; Nick Barrowman; Faisal Rehman; Doug Matsell; M Patricia Rosas-Arellano; Marina Salvadori; R Brian Haynes; William F Clark
Journal:  JAMA       Date:  2003-09-10       Impact factor: 56.272

Review 9.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

Review 10.  Initiation of complement activation following oxidative stress. In vitro and in vivo observations.

Authors:  Melanie L Hart; Mary C Walsh; Gregory L Stahl
Journal:  Mol Immunol       Date:  2004-06       Impact factor: 4.407

View more
  17 in total

1.  Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.

Authors:  Véronique Frémeaux-Bacchi; Anne-Laure Sellier-Leclerc; Paula Vieira-Martins; Sophie Limou; Theresa Kwon; Annie Lahoche; Robert Novo; Brigitte Llanas; François Nobili; Gwenaëlle Roussey; Mathilde Cailliez; Tim Ulinski; Georges Deschênes; Corinne Alberti; François-Xavier Weill; Patricia Mariani; Chantal Loirat
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-23       Impact factor: 8.237

2.  CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).

Authors:  Caroline Caillaud; Ariane Zaloszyc; Christoph Licht; Valérie Pichault; Véronique Frémeaux-Bacchi; Michel Fischbach
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

3.  C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Luciana Meni Bataglia; Ismael Toledo; Laura Beaudoin; Caupolican Alvarado
Journal:  Pediatr Nephrol       Date:  2019-09-02       Impact factor: 3.714

4.  Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.

Authors:  Lucas Percheron; Raluca Gramada; Stéphanie Tellier; Remi Salomon; Jérôme Harambat; Brigitte Llanas; Marc Fila; Emma Allain-Launay; Anne-Laure Lapeyraque; Valerie Leroy; Anne-Laure Adra; Etienne Bérard; Guylhène Bourdat-Michel; Hassid Chehade; Philippe Eckart; Elodie Merieau; Christine Piètrement; Anne-Laure Sellier-Leclerc; Véronique Frémeaux-Bacchi; Chloe Dimeglio; Arnaud Garnier
Journal:  Pediatr Nephrol       Date:  2018-03-23       Impact factor: 3.714

5.  Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.

Authors:  Ayşe Ağbaş; Nilüfer Göknar; Nurver Akıncı; Zeynep Yürük Yıldırım; Mehmet Taşdemir; Meryem Benzer; İbrahim Gökçe; Cengiz Candan; Nuran Küçük; Selçuk Uzuner; Gül Özçelik; Demet Demirkol; Lale Sever; Salim Çalışkan
Journal:  Pediatr Nephrol       Date:  2018-08-29       Impact factor: 3.714

6.  HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.

Authors:  Carla Galvez; Paola Krall; Alejandro Rojas; Jun Oh; Francisco Cano
Journal:  Pediatr Nephrol       Date:  2022-08-15       Impact factor: 3.651

Review 7.  Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Authors:  Carlamaria Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2017-12-06       Impact factor: 3.714

Review 8.  Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Ramon Alfonso Exeni; Romina Jimena Fernandez-Brando; Adriana Patricia Santiago; Gabriela Alejandra Fiorentino; Andrea Mariana Exeni; Maria Victoria Ramos; Marina Sandra Palermo
Journal:  Pediatr Nephrol       Date:  2018-01-25       Impact factor: 3.714

9.  Eculizumab in STEC-HUS: need for a proper randomized controlled trial.

Authors:  Sebastian Loos; Jun Oh; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2018-05-17       Impact factor: 3.714

10.  Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study.

Authors:  Lucia Karnisova; Ondrej Hradsky; Kveta Blahova; Filip Fencl; Zdenek Dolezel; Tomas Zaoral; Jakub Zieg
Journal:  Eur J Pediatr       Date:  2018-09-24       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.